Did you arrive here by via search engine?
Click here to view the original version of this article

Click to Print This Page
(This section will not print)

GI Manifestations of Covid-19
Max Schmulson, M.D., R.F.F.

Dr. Max Schmulson is Professor of Medicine at the Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.

Within the past 12 months, Dr. Schmulson has been on the Speakers Bureau for Takeda Mexico, received research support from Takeda Mexico and Alfa Sigma Mexico, and been a consultant for Gemelli Biotech.

Albert Einstein College of Medicine – Montefiore Medical Center CCPD staff and interMDnet staff have nothing to disclose relevant to this activity.

Release Date: 07/08/2020
Termination Date: 07/07/2023

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • List the diverse GI manifestations of COVID-19 illness.
  • Describe the underlying mechanisms of GI symptoms in patients with COVID-19.
  • Anticipate the possibility of diagnosing of SARS-CoV-2 infection in stools and monitor potential preventive measures for fecal-oral transmission.


The coronavirus disease-2019 (COVID-19), the clinical name of the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection that originated in the city of Wuhan, province of Hubei in China, in December 2019, was declared a pandemic by the World Health Organization on March 11, 2020.(1)

At the beginning of May 2020, the Centers for Disease Control and Prevention (CDC) in the United States recognized the presence of “gastrointestinal symptoms, like nausea, vomiting and diarrhea, as less common symptoms” of COVID-19 after cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell.(2) At the time, there were already several reports from China,(3)(4) Singapore(5) and Europe(6) that had noted the presence of gastrointestinal symptoms (GI) in patients with COVID-19. These digestive manifestations were later confirmed in the United States(7) and more recently in Mexico.(8) At least four papers have reviewed the literature concerning the presence of GI symptoms in patients with COVID-199-12 (see Table 1).

Table 1. Summary of Review Papers that Analyzed Gastrointestinal Symptoms Among Patients with COVID-19.

Authors Studies
Patients (N) Diarrhea Nausea Vomiting Abdominal
Anorexia Belching
GI Bleeding
Tian et al. 15 2023 2.0-49.5% 1.0-29.4% 3.6-66.7% 2.2-6.0% 39.9-50.2% -- 4.0-13.7%
Schmulson et al. 15 2800 2.0-24.2% 1.0-17.9% 1.7-5.0% 2.0-5.8% 10.0-40.7% 2.1-5.0% --
Cheung et al. 60 4243 12.5% (95% CI: 9.6–16.0) Inc. in Vomit. 10.2% (95% CI: 6.6–15.3) 9.2% (95% CI: 5.7–14.5)* 26.8% (95% CI: 16.2–40.8) -- --
Mao et al. 29 6064 1.0-34.0% Inc. in Vomit. 1.0-22.0% 1.0-4.0% 1.0-79.0% -- --

Results are reported in prevalence ranges except for Cheung KS et al. who reported mean prevalence and 95% confidence intervals (CI).

“Inc. in Vomit.” (included in vomiting) refers to reviews that analyzed the prevalence of nausea together with vomiting.

*This review reported abdominal pain combined with abdominal discomfort.

The first review among 2023 patients found GI symptom incidence varied from 3% to 79%.(9) The second review of fifteen articles with 2,800 patients found a frequency of GI symptoms that ranged from 3.0% to 39.6%, of which diarrhea was the most common symptom.(10) A third review and meta-analysis (29 studies including 6064 patients with reported GI symptoms in patients with COVID-19) calculated a pooled prevalence of digestive symptoms of 15% (95% CI: 10-21; range: 2–57%; I2=96%).(11) Among them nausea or vomiting, diarrhea and loss of appetite were the three most common symptoms.(11) Another review and meta-analysis of 4243 patients that included 53 studies from China, two from South Korea, two from Singapore, one from Vietnam, one from the U.S. and one from the United Kingdom reported a pooled prevalence of all GI symptoms of 17.6% (95% CI: 12.3%. 24.5%).(12) There was a higher prevalence of GI symptoms in patients with severe vs. non-severe COVID-19 illness, 11.8% (95% CI: 4.1%-29.1%) vs. 17.1% (95% CI: 6.9%-36.7%), respectively.(12)

It is interesting to note that besides diarrhea, nausea, vomiting, abdominal pain, bloating, burping and anorexia, gastrointestinal bleeding has also been reported in some patients. Upper GI bleeding has been related to herpetic erosions and ulcers,(13) while hematochezia has been present in some patients without any identified source, or due to hemorrhagic colitis with patchy erythema, circumferential wall thickening, mesenteric hypervascularity and pericolic fat stranding (appearance of edema within fat).(14)(15)

The majority of the above analyzed studies included hospitalized patients. However, a study from outpatient settings in New York of patients with SARS-CoV-2 confirmed by PCR of nasopharyngeal swabs found a GI symptom prevalence of 35%. Also, the presence of GI symptoms was associated with a 70% increased risk of testing positive for COVID-19 infection (adjusted OR: 1.7, 95% CI: 1.1-2.5).(16)

GI symptoms are also present in pediatric patients with COVID-19. For example, in the systematic review and meta-analysis by Mo et al., pediatric patients had a similar prevalence of Gl symptoms to those of adult patients.(11) In 10% of the children with COVID-19, GI symptoms were the only ones without respiratory manifestations, and patients with GI symptoms had delayed diagnosis of 2.85 days (95% CI: 0.22–5.48) and had a higher prevalence of complications.(11) In a systematic review and meta-analysis of nine case-series, 75% of the children had household contacts; and while fever and cough were the most common manifestations, GI symptoms were present in 12% of the children.(17)

In addition, it is important to mention that liver function abnormalities are also common in COVID-19 patients,(11) primarily manifested as moderate elevations of serum aminotransferases levels.(18) In a study among 417 patients with COVID-19, 76.3% had abnormal liver test results and 21.5% had liver injury during hospitalization.(19) Also, these patients were at higher risk of progressing to severe disease.(19) However, the exact cause of the liver damage has not been elucidated and there is insufficient evidence for direct viral liver injury.(20)(21) Several reasons have been proposed for the hepatic abnormalities in COVID-19, including viral infection per se, use of potentially hepatotoxic drugs, systemic inflammatory response, hypoxia and multiple organ dysfunction.(18) The effect of COVID-19 on the liver is beyond the scope of this paper and will not be further addressed.

GI Symptoms As Atypical Manifestation of COVID-19

There is evidence that GI symptoms can also be atypical manifestations of COVID-19. For example, Pan L. et al. reported that 7% of their 204 patients in the province of Hubei in China presented with digestive symptoms only.(4) Of this group, 48.5% arrived at the hospital with GI symptoms as their chief complaint and in seven cases they were the only manifestations, that is, these seven patients did not have respiratory symptoms. Patients with digestive symptoms had a significantly longer time interval from onset to admission compared to those with no digestive symptoms (almost two days longer).(4) In another study from the province of Hubei, with more than half of the patients from the city of Wuhan, Liu K. et al. found a prevalence of diarrhea of 8%. Interestingly, 20% of their patients did not develop fever, and in some patients, digestive symptoms were among the initial manifestations.(22)(23) In a series from the city of Zhuhai, in the province of Guandong, more than 61% of their 95 patients presented with GI symptoms, and 81% developed these symptoms during the course of hospitalization.

Furthermore, 11.6% of the patients did not have imaging features of COVID-19 pneumonia, only GI manifestations.(13) In a study on 651 cases from the province of Zhejiang, 28.4% of their patients lacked respiratory symptoms and only presented with GI symptoms such as nausea, vomiting and diarrhea. The median duration of the diarrhea was four days, ranging from one to nine days, and was self-limited in the majority of cases.(24)24 In the city of Veracruz, in the south of Mexico, among 112 patients who consulted a private hospital, 20.5% reported at least one GI symptom, of which the most common ones were diarrhea (17.8%), abdominal pain (9.8%), and vomiting (7.1%). Similarly, in 6.2% of the cases, these were the only clinical manifestations.(8)

GI Symptoms and Severity of COVID-19

In a study from the city of Wuhan, the frequency of GI symptoms was compared between patients hospitalized or not in the ICU. Only abdominal pain was more common in patients in the ICU (8.3% vs. 0.0%, p=0.02).25 Another study from the city of Zhuhai found no differences in hospital stay, discharge or mortality in patients with or without GI symptoms.(13) In the first study from Singapore of 18 hospitalized patients, none of the three patients with diarrhea required supplemental oxygen.(5) In the study from outpatients settings in New York, there was a trend toward lower rate of ICU admission, and a significantly lower rate of death in patients with vs. without GI symptoms (0.0% vs. 5.0%, p=0.03), during a short-term follow-up.(16)

The last three case series described above possibly suggest a milder outcome in patients with digestive symptoms, such as abdominal pain and diarrhea.(25)(26) In contrast, to the previous studies, Pan et al. reported that patients with digestive symptoms were half as likely to be cured and discharged than the 60% without GI symptoms.(4) Also, Jin et al. in Zhejiang, China reported that the presence of acute respiratory distress syndrome and the need for mechanical ventilation were significantly more frequent in patients with GI symptoms compared to those without.(24) A large study from Chile of 7,016 patients who tested positive for SARS-CoV-2, of whom 7.3% had diarrhea and 3.7% abdominal pain, diarrhea was associated with a higher risk of hospitalization (RR: 1.31, 95% CI: 1.1-1.57; p<0.01) but abdominal pain was not.(27)

Others were unable to discriminate the severity of COVID-19 according to the presence or not of GI symptoms.(3)(28) Notwithstanding, in a pooled analysis of 10 studies including 1,989 patients with COVID-19, of whom 30.1% were classified as severe disease, abdominal pain was found to be associated with a nearly four-fold increased odds of severe illness, with a marginally significant increased prevalence for nausea and vomiting, but not for diarrhea.(29)

Potential Underlying Mechanism for GI symptoms in COVID-19

To infect the human cells, the SARS-CoV-2 requires binding to the angiotensin-converting enzyme 2 (ACE2) receptor.(30) This process begins by the interaction of the spike glycoprotein (S) and the ACE2. Following this engagement, SARS-CoV-2 S is processed by a plasma membrane-associated transmembrane serine proteases, TMPRSS2 and TMPRSS4, promoting the virus entry into the host cells.(31)(32) Although ACE2 receptors have been identified in type II alveolar cells of the lung, myocardial cells, kidney proximal tubule cells and bladder urothelial cells,(33)(34) they are also present in cholangiocytes and in the digestive tract.(35) In the GI tract, they are mainly localized in glandular cells of the stomach, duodenum and rectum, and are rarely identified in the esophagus probably because of its predominance of squamous epithelial cells.(36) As ACE2 receptors have been shown to be expressed in the oral cavity mucosa and are highly enriched in the epithelial cells of the tongue, the oral cavity and digestive tract may be a route of infection of this novel virus.(33)(34)(37)(38) Furthermore, viral replication has been demonstrated in enteric cells(39) and SARS-CoV-2 RNA has been detected in the esophagus, stomach, duodenum and rectum.(13)

There is also evidence that the SARS-CoV-2 infection in patients without inflammatory bowel disease (IBD) triggers an inflammatory response in the gut. This response is not only clinically manifested (e.g., diarrhea), but also presents with intestinal infiltration of neutrophils, macrophages and T cells, elevated fecal calprotectin and a systemic IL-6 response.(40) The increased level of fecal calprotectin was shown to be significantly higher in COVID-19 patients with ongoing diarrhea and in those in whom the diarrhea had ceased compared to patients without diarrhea.(40) This inflammatory response may be responsible for the presence of the round herpetic erosions and ulcers in the esophagus that have been found in some patients with GI bleeding,(13) or aphthous lesions in the terminal ileum that mimic Crohn’s disease.(41)

SARS-CoV-2 RT-PCR in Feces

SARS-Cov-2 viral nucleic acids have not only been uncovered in respiratory samples, but are also present in saliva and stools.(5)(42) For example, Zhang JC, et al. reported that the nucleic acid detection of COVID‐19 in fecal specimens was as accurate as pharyngeal swab specimens, despite the fact that patients with a positive stool test did not necessarily experience GI symptoms.(43) In the Singapore case series, the virus was detected in the stools of 4 out of 8 patients that were tested, regardless of the presence of diarrhea;5 and in another study, the presence of viral RNA in feces was not related to the presence or severity of GI symptoms.(13) More importantly, a group from China found that viral RNA was still present in the stools of more than 20% of the patients infected with SARS-Cov-2 that had a negative conversion of the viral RNA in the respiratory tract.(35)

In a study of 206 patients with mild COVID-19 disease, 117 (56.7%) presented digestive symptoms, with or without respiratory symptoms. Those with digestive symptoms were more likely to be fecal virus positive (73.3% vs. 14.3%, p=0.033) vs. those with only respiratory symptoms, and patients who were positive for viral RNA in stools had longer time to viral clearance compared to those who were negative (44.2 vs. 33.7 days, p=0.003).(44) In addition, there have been reports of viral viability including survival up to two weeks in a maintenance medium containing the virus dried at room temperature.(42)(45) Extended viral viability, together with the presence of virus in the feces, support the possibility of fecal-oral transmission, especially in areas with poor sanitation.(42)(45)

Stool Testing

Despite the reports of fecal shedding of viral RNA, there are, currently, no guidelines for stool testing in patients suspected of being infected with COVID-19. However, considering the high prevalence of positive stools in a group of patients, some experts advocate for routine RT-PCR testing of feces, especially in patients presenting with digestive symptoms.(44) Multi-sample testing may potentially improve diagnostic accuracy. One study reported, for example, positivity of nasopharyngeal swab at 38.13%, sputum at 48.68%, blood 3.03%, feces 9.83% and anal swabs at 10.0%.(46)

Another important issue to consider is that wastewater surveillance may provide epidemiological information about the viral circulation in a specific community.(47) Accordingly, in the region of Murcia in Spain, surveillance of titers of SARS-CoV-2 in the wastewaters determined that citizens were shedding virus even before the first cases were reported.(48) Therefore, wastewater-based epidemiology, by monitoring viral RNA, can be used to assess disease prevalence and spread in defined populations, providing important information for implementing public health policies.(49)

Preventive Measures

Aerosolization of the virus may be a risk during upper GI endoscopic procedures or breath tests.(45)(50) This, together with the possibility of viral shedding in the feces, prompts the need for preventive measures in endoscopy units, as well as in motility labs during the performance of colonoscopies or anorectal manometries and biofeedback, respectively.(51)(52)(53) These measures should be taken to protect healthcare personnel against contracting infections while performing gastrointestinal endoscopic and/or manometric procedures and breath testing. However, they are beyond the scope of the current review but can be summarized as delaying elective procedures up to eight weeks or until the pandemic declines, implementing a pre-procedural triage and using personal protective equipment (PPE) if there is a time-sensitive endoscopic procedure that needs to be performed.(54)

In addition, toilet flushing can produce aerosols, resulting in fomite transmission,(55) with droplet nuclei that are small enough to both contaminate surfaces and become airborne.(50)50 Apparently, the SARS-CoV-2 can live in aerosols for three hours.(56) In China, the presence of GI symptoms was related to family clustering.(24) Therefore, toilet isolation measures should be implemented in households with positive cases of COVID-19.(10) Fecal shedding could also be a mode of transmission in hospital settings or public places, including schools, stadiums or theaters. It is important to underscore that fecal shedding can occur even in asymptomatic subjects or patients with mild symptoms and delayed diagnosis.(44) Therefore, until research studies clarify whether toilet flushing produces bio-aerosolized and viable SARS-CoV-2, it is recommended to use lids on toilettes(50) and to close them before flushing. According to the author, educational campaigns in this regard, as well as on handwashing, are needed, and include pasting instruction posters in public restrooms.

Table 2. Preventive Measures Against Fecal-oral Transmission.

Focus Actions
Endoscopy Units and Motility Labs • Delay elective procedures up to eight weeks or until the pandemic declines
• Pre-procedural triage
• Use personal protective equipment (PPE)
• Implement equipment and surfaces disinfection
• Proper disinfection of hospital sewage
• Ensure environmental decontamination protocols (ventilation systems)
Household contacts • Bathroom isolation
• Use only your dishes and utensils
Toileting • Lids on toilets or use non-flushing commodes
• Flush with the lid down
• Strict hand washing

Treatment of GI symptoms In Patients With COVID-19

There are no treatments that have been tested in patients with COVID-19 and GI symptoms. In patients with diarrhea, dehydration is possible and, therefore, fluid replacement is important. In the experience of the author caring for outpatients with COVID-19 and digestive symptoms, symptomatic treatment is useful. Such treatments can include antispasmodics for abdominal pain and probiotics in patients with diarrhea. Still, the most important issue is to be aware that GI symptoms can be a manifestation of COVID-19 even in the absence of fever or respiratory symptoms, and the healthcare professional must consider ruling out this viral infection, especially in patients with novel GI symptoms and in whom other causes are excluded.(10)


It is now well demonstrated that patients with COVID-19 may present with GI symptoms as the initial manifestation of this pandemic or during the course of the illness. In some cases, the GI symptoms can be the sole manifestation of the viral infection, thus considered atypical COVID-19 cases.

The frequency of the GI symptoms varies widely and include diarrhea, nausea, vomiting, abdominal pain, bloating, burping/reflux and even GI bleeding. There is controversy as to whether these digestive symptoms are related to the illness prognosis, although a pooled analysis found a relationship between abdominal pain and severe disease.

The possible explanation for the GI symptoms is the need of SARS-CoV-2 virus to bind to the ACE2 receptor to infect the human cells; a receptor whose largest expression is in the enteric epithelial cells. In addition, fecal viral shedding has been well demonstrated, hence there is a possibility of fecal-oral transmission. More studies are warranted to determine the potential of fecal testing in the diagnosis of COVID-19, especially in those who have negative pharyngeal swabs. In the meantime, bathroom isolation for infected household contacts and preventive measures in public bathrooms are recommended.


1Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020;76:71-76.
2Centers for Disease Control and Prevention CDC. Symptoms of Coronavirus. In: CDC, ed. Coronavirus Disease 2019 (COVID-19). . Volume 2020. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html, 2020.
3Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
4Pan L, Mu M, Gang Ren H, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020.
5Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020.
6Spiteri G, Fielding J, Diercke M, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill 2020;25.
7Redd WD, Zhou JC, Hathorn KE, et al. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study. Gastroenterology 2020.
8Remes-Troche JM, Ramos-de-la-Medina A, Manríquez-Reyes M, et al. Initial Gastrointestinal Manifestations in Patients with SARS-CoV-2 in 112 patients from Veracruz (Southeastern Mexico). Gastroenterology 2020.
9Tian Y, Rong L, Nian W, et al. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020;51:843-851.
10Schmulson M, Davalos MF, Berumen J. Beware: Gastrointestinal symptoms can be a manifestation of COVID-19. Rev Gastroenterol Mex 2020.
11Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020.
12Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. Gastroenterology 2020.
13Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 2020.
14Guotao L, Xingpeng Z, Zhihui D, et al. SARS-CoV-2 infection presenting with hematochezia. Med Mal Infect 2020;50 293-296.
15Carvalho A, Alqusairi R, Adams A, et al. SARS-CoV-2 Gastrointestinal Infection Causing Hemorrhagic Colitis. Am J Gastroenterol 2020;115 942-946.
16Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States. Gastroenterology 2020.
17Chang TH, Wu JL, Chang LY. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. J Formos Med Assoc 2020;119:982-989.
18Feng G, Zheng KI, Yan QQ, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol 2020;8:18-24.
19Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020.
20Wu J, Song S, Cao HC, et al. Liver diseases in COVID-19: Etiology, treatment and prognosis. World J Gastroenterol 2020;26:2286-2293.
21Li J, Fan JG. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. J Clin Transl Hepatol 2020;8:13-17.
22Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
23Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020.
24Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020.
25Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.
26Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.
27Diaz LA, Garcia-Salum T, Fuentes-Lopez E, et al. Symptom profiles and risk factors for hospitalization in patients with SARS-CoV-2 and COVID-19: A Large Cohort from South America. Gastroenterology 2020.
28Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020.
29Henry BM, de Oliveira MHS, Benoit J, et al. Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. Intern Emerg Med 2020.
30Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181:271-280 e8.
31Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol 2020;5.
32Uno Y. Camostat mesilate therapy for COVID-19. Intern Emerg Med 2020.
33Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020.
34Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020;7:11.
35Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020.
36Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 2020;158:1831-1833 e3.
37Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv 2020.
38Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12:8.
39Zhang H, Li HB, Lyu JR, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis 2020;96:19-24.
40Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut 2020.
41Parigi TL, Bonifacio C, Danese S. Is it Crohn's disease? Gastroenterology 2020.
42Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 2020.
43Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. J Med Virol 2020.
44Han C, Duan C, Zhang S, et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol 2020.
45Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol 2020;5:335-337.
46Wu J, Liu J, Li S, et al. Detection and analysis of nucleic acid in various biological samples of COVID-19 patients. Travel Med Infect Dis 2020:101673.
47Lodder W, de Roda Husman AM. SARS-CoV-2 in wastewater: potential health risk, but also data source. Lancet Gastroenterol Hepatol 2020;5:533-534.
48Randazzo W, Truchado P, Cuevas-Ferrando E, et al. SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area. Water Res 2020;181:115942.
49Nghiem LD, B. M, Donner E, et al. The COVID-19 pandemic: considerations for the waste and wastewater services sector Case Studies in Chemical and Environmental Engineering 2020.
50McDermott CV, Alicic RZ, Harden N, et al. Put a lid on it: Are faecal bio-aerosols a route of transmission for SARS-CoV-2? J Hosp Infect 2020.
51MESSAGE JGS. COVID-19 Use of Personal Protective Equipment in GI Endoscopy, 2020.
52Sociedad Espanola de Patologia D, Asociacion Espanola de G. Recommendations by the SEPD and AEG, both in general and on the operation of gastrointestinal endoscopy and gastroenterology units, concerning the current SARS-CoV-2 pandemic (March, 18). Rev Esp Enferm Dig 2020.
53Baker JR, Moshiree B, Rao S, et al. American Neurogastroenterology and Motility Society (ANMS) Task Force Recommendations for Resumption of Motility Laboratory Operations During the COVID-19 Pandemic. American Neurogastroenterology and Motility Society 2020;https://motilitysociety.org/pdf/ANMS_Task_Force_COVID_Recommendations_May_2020.pdf.
54Sultan S, Lim JK, Altayar O, et al. AGA Institute Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology 2020.
55Wong SH, Lui RN, Sung JJ. Covid-19 and the Digestive System. J Gastroenterol Hepatol 2020.
56van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020;382:1564-1567.